Trial Profile
A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2020
Price :
$35
*
At a glance
- Drugs Onvansertib (Primary)
- Indications Carcinoma; Colon cancer; Colorectal cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Lung cancer; Ovarian cancer; Pancreatic cancer; Periampullary cancer; Prostate cancer; Skin cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Nerviano Medical Sciences
- 20 Jul 2017 Results published in the Investigational New Drugs
- 25 May 2017 Data from this trial is being submitted for peer review publication by study investigators, as reported in a TrovaGene Media Release
- 25 May 2017 Results published in the TrovaGene Media Release